Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue
Mandate

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

October 22, 2024 M&A

Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.

The new shares issued in the rights issue are expected to be admitted to trading on Nasdaq Stockholm on or around 22 October 2024. Vicore is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is advancing a portfolio of therapies in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's shares are listed on Nasdaq Stockholm.

Vinge’s team consisted primarily of Rikard Lindahl, Joel Magnusson, Annie Fällström and Carl Lexenberg.

Related

Vinge has advised Skeptiva AB in connection with its financing round

 Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

 Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026

Vinge represents Studsvik AB (publ) in the acquisition of Kärnfull Next AB

 Vinge has represented Studsvik AB (publ) in connection with the acquisition of Kärnfull Next AB, a company developing methods for building small modular nuclear reactors.
March 10, 2026